<DOC>
	<DOC>NCT00329628</DOC>
	<brief_summary>The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.</brief_summary>
	<brief_title>Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male and female patients aged 18 years or above Patients scheduled for elective total hip replacement Planned, staged total bilateral hip replacement Active bleeding or high risk of bleeding contraindicating treatment with low molecular weight heparin Contraindication listed in the labeling or conditions precluding patient treatment with enoxaparin Conditions prohibiting bilateral venography (e.g. amputation of one leg, allergy to contrast media)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Thromboembolism</keyword>
</DOC>